Page 2520 - Williams Hematology ( PDFDrive )

2491
2490 Index Index 2491

hemoglobin polymerization, 763–764 intermediate, 1353 Skeletal survey, in myeloma, 1715, 1748,
hemolysis and nitric oxide scavenging, in megaloblastic anemia, 595 1748f
764 morphology, 915–916 Skin disorders
inflammation and chronic vasculopathy, normal, 465, 552, 623–624, 916f in acute myelogenous leukemia, 1380,
765 pathologic, 465, 466f, 916f 1410
ischemia–reperfusion injury, 765 ring, 178, 465, 567, 624, 918, 1353 in adult Langerhans cell histiocytosis, 1108
in pregnancy, 125–126 Siderocyte, 467f in antiphospholipid syndrome, 2240
transient aplastic crisis and, 541 Siderosomes, 465, 468 in chronic lymphocytic leukemia, 1541
treatment, 774–776 Siglec1 (sialoadhesin), 1054, 1080, 1081f, eosinophils and, 954, 956t
DNA methyltransferase inhibitors, 775 1082, 1083f in Erdheim-Chester disease, 1111
fetal hemoglobin-inducing agents, Siglec-2. See CD33 hemorrhage, 1987
774–775 Siglec 8, 949 history of, 6
gene therapy, 453 Siglec 10, 949 in juvenile xanthogranuloma, 1112
hematopoietic cell transplantation, Signaling lymphocyte activation molecule in Langerhans cell histiocytosis,
362–363, 775 (SLAM), 54 1103–1104, 1103f, 1106
histone deacetylase inhibitors, 775 Signal transduction pathways, 247–253 in mycosis fungoides. See Mycosis
hydroxyurea, 774, 774t, 775f apoptosis and, 208–209, 208f fungoides (MF)
investigative, 776, 777t BCR-ABL1 and, 1443–1444, 1444f primary lymphomas, 1581, 1665
iron overload associated with, 776 coordination and crosstalk, 253 in Rosai-Dorfman disease, 1113
potential targets, 767t downstream signals, 250–252, 251f in systemic mastocytosis, 973–974, 974f
red cell exchange, 430t, 431–432 extinguishing signals in, 252–253 in Waldenström macroglobulinemia, 1791
transfusions, 776, 2371–2372 insulation, 252 warfarin-related necrosis, 396, 2100, 2100f,
Sickle cell-Hb C disease, 762 metabolism and, 193–196, 194f, 195f 2223
Sickle cells (drepanocytes), 473f, 473t, 474f, overview, 247 Skin examination, 7–8
475 in platelets. See Platelets, signaling Skp2, 217
Sickle cell thalassemia, 749 pathways Skull lesions, in Langerhans cell histiocytosis,
Sickle cell trait (hemoglobin AS), 762, 766 receptors, 247–250, 248f. See also specific 1104, 1106
Side-population cells, 450 receptors SLAM (signaling lymphocyte activation
Sideroachrestic anemia, 1342 specificity within receptor families, 252 molecule), 54
Sideroblastic anemias, 915–920 Silent alleles, blood group, 2339 SLC1A5 (ASCT2), 197, 198
classification, 916t Silent β-thalassemia, 733, 750 SLC2A1 (GLUT1), 192
clinical and laboratory features, 920 Siltuximab SLC4A1, 664
definition and history, 915 for Castleman disease, 1250 SLC11A1 (Nramp1), 621, 1010, 1014
differential diagnosis, 637 for myeloma, 345f, 346t SLC11A3. See Ferroportin (SLC40A1,
drugs causing, 916t, 919 Single-molecule sequencing, 158–159, 158f SLC11A3)
epidemiology, 915 Single nucleotide polymorphism (SNP), 147, SLC19A2, 652
hereditary 174 SLC25A38, 916
autosomal, 890–891 Singlet oxygen, 284t, 286 SLC40A1. See Ferroportin (SLC40A1,
Pearson marrow-pancreas syndrome, Sinus histiocytosis with massive SLC11A3)
919, 920 lymphadenopathy (Rosai-Dorfman SLE. See Systemic lupus erythematosus (SLE)
X-linked, 894, 916–917, 920 disease), 1101, 1112–1113 SM (Sec1/Munc18), 1849
X-linked with ataxia, 918 Sinusoidal obstructive syndrome (SOS), 368 SMAC, 204f, 208, 1186
mitochondrial myopathy and, 919 SIN (self-inactivating) viral vectors, 437 SMAD, 251, 1713
pathogenesis siRNA, 153 SMAD4, 621t
anemia mechanism, 919 Sirolimus SMAD anchor for receptor activation
heme synthesis defects, 916 for APECED syndrome, 1224 (SARA), 251
metabolic defects, 918 in drug-eluting stents, 2297 Small G proteins, 1882–1883
mitochondrial myopathy, 919 for Erdheim-Chester disease, 1111 Small immature monocyte, 1045
morphology, 915–916, 916f for IPEX syndrome, 1223 Small lymphocytic lymphoma (SLL), 184t,
pyridoxine metabolism, 917–918 Site I, 248 1533, 1592–1593, 1592f
ring sideroblast formation, 918 Site II, 248 Small noncleaved cell (non-Burkitt)
primary acquired (clonal), 918–919 Sitosterolemia, 1996 lymphoma, 187
secondary acquired, 919–920 Sjögren syndrome Small ubiquitin-like modifier (SUMO), 253
treatment, 920 lymphocytopenia in, 1206 SMARCAL1, 1226
Sideroblasts lymphomas and, 1574–1575, 1664 SMC1A, 1346t, 1352
absence of, 552 neutropenia in, 996 SMC3, 1346t, 1352

Kaushansky_index_p2393-2506.indd 2491 9/21/15 3:22 PM